The firm also said it will wind down its microbiome laboratory and analytical sequencing services business, expecting annual cost savings of $10 million.

The man had, among other things, fraudulently billed Medicare and other healthcare benefit programs for medically unnecessary cancer genomic tests.

NEW YORK – Danaher announced on Thursday that it is partnering with Johns Hopkins University to develop methods to diagnose mild traumatic brain injuries. Through the collaboration, Johns Hopkins ...

The firm reported rising revenues across its prenatal, pharmacogenomics, and hereditary cancer testing businesses, although its tumor profiling business dipped year over year.

NEW YORK – iHealth Labs announced on Wednesday that its antigen test for COVID-19 and influenza A/B has received Emergency Use Authorization from the US Food and Drug Administration. The 3-in-1 ...

The new agreement builds on a previous partnership to develop a MeMed immunoassay for Beckman's Access family of analyzers.

The firm reported rising non-COVID diagnostics revenues in the EMEA and Americas regions plus gains from an ongoing transformation program.

The hub will support the development of diagnostics and medical devices to detect, prevent, or respond to medical consequences that result from health security threats.

The Tennessee-based firm is combining molecular and protein testing technologies that it brought under one roof in a pair of deals last summer.

Last week, readers were most interested in a story about the release of FDA's final rule for regulating laboratory-developed tests.

NEW YORK – With technologies brought under one roof through a pair of deals last summer, New Day Diagnostics aims to complete within the next two years the development of a blood-based screening test ...

Infectious disease firm Karius announced on Thursday that it has raised $100 million in a Series C financing round with new and existing investors. The funding round ...